Similar Items: Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
- Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies
- Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study
- Herpes Zoster Risk in Rheumatoid Arthritis Patients on Janus Kinase Inhibitors: A 17-Year Experience from Rheumatoid Arthritis Saudi Database (RASD)
- Correction to “Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders”
- Characterizing Adherence to a Mobile Health App for Patient-Reported Outcomes in Rheumatoid Arthritis
- Mycobacterium Intracellulare Infection of the Metacarpophalangeal Joint in a Patient With Rheumatoid Arthritis: A Case Report